| | study | Luangchosiri et al. 2015 [19] | Marjani et al. 2016 [20] | Zhang et al. 2016 [21] | Gu et al. 2015 [42] | Heo et al. 2017 [43] |
| | design | Randomized
double-blind
controlled trial | randomized
double blind | randomized controlled
open labelled | open-label randomized multi-center | Prospective
Randomized
double-blind placebo-controlled | | patients randomized | 58 | 72 | 379 | 568 | 121 | | age | 56.00 | 50.10 | < 41 years, 180
⩾41 years, 190 | 37.42 ± 14.28 | 57.73 ± 13.94 | | male | 22(40.00) | 37 (52.86) | 274(74.05) | 374(65.85) | 68(66.02) | | diagosis | pulmonary TB | diagnosed of TB | diagnosed of TB | diagnosed of TB and having primary pulmonary TB | diagnosed of TB | | anti-TB regimen | standard regimen consisting isoniazid (5 mg/kg), rifampin (10 mg/kg), pyrazinamide (25 mg/kg) and ethambutol (15 mg/kg) | standard regimen consisting isoniazid (5 mg/kg), rifampin (10 mg/kg), pyrazinamide (20 mg/kg) and ethambutol (15 mg/kg) | the standard anti-tuberculosis therapy including isoniazid (H), rifampicin (R), pyrazinamide (Z), and thambutol (E) | the standard anti-TB treatment drugs including isoniazid (H), rifampicin (R), pyrazinamide (Z), and thambutol (E) | the first line standard anti-TB treatment drugs including isoniazid, rifampicin, ethambutol and pyrazinamide | | experimental group | silymarin, 140 mg, tid | sylibum marianum ( equivalent to 140 mg silymarin), tid | silybum marianum, 200 mg, bid | silibinin, 70 mg, tid | silymarin, 140 mg, bid | | control group | placebo, tid | placebo, tid | vitamin C, bid | none | placebo, bid | | follow-up | week 2, 4 | week 2 | week 8 | Week2, 4, 8 | Week 2, 4, 8 | | Country | Thailand | Iran | China | China | Korea | | Outcomes | ①②④ | ①④ | ①②③④ | ①②③④ | ①②③ |
|
|
Values are presented as number (%) or mean±SD.
①: the occurrence of anti-TB treatment related DILI; ②: liver function tests (ALT, AST, ALP, and TBIL); ③: the occurrence of interruption of anti-TB treatment or taking the second-line TB drugs; ④: adverse events.
|
